Skip navigation
  • Home
  • Browse
    • Communities
      & Collections
    • Browse Items by:
    • Publication Date
    • Author
    • Title
    • Subject
    • Department
  • Sign on to:
    • My MacSphere
    • Receive email
      updates
    • Edit Profile


McMaster University Home Page
  1. MacSphere
  2. Departments and Schools
  3. Faculty of Health Sciences
  4. Medicine
  5. Medicine Publications
Please use this identifier to cite or link to this item: http://hdl.handle.net/11375/29541
Title: Effect of colchicine on perioperative atrial fibrillation and myocardial injury after noncardiac surgery in patients undergoing major thoracic surgery – the COP-AF randomised controlled trial
Other Titles: COP-AF
Authors: Conen, David
Wang, Michael Ke
Popova, Ekaterine
Chan, Matthew TV
Landoni, Giovanni
Cata, Juan P.
Reimer, Cara
McLean, Sean R.
Srinathan, Sadeesh K.
Trujillo Reyes, Juan Carlos
Grande, Ascension Martín
Gonzalez Tallada, Anna
Sessler, Daniel I.
Fleischmann, Edith
Kabon, Barbara
Voltolini, Luca
Cruz, P.
Maziak, Donna E.
Gutiérrez-Soriano, Laura
McIntyre, William F.
Tandon, Vikas
Martínez-Téllez, Elisabeth
Guerra-Londono, Juan Jose
DuMerton, Deborah
Wong, Randolph HL
McGuire, Anna L.
Kidane, Biniam
Parise Roux, Diego
Shargall, Yaron
Wells, Jennifer R.
Ofori, Sandra N.
Vincent, Jessica
Xu, Lizhen
Li, Zhuoru
Eikelboom, John W.
Jolly, Sanjit S.
Healey, Jeff S.
Devereaux, PJ
Department: Medicine
Keywords: Colchicine;inflammation;atrial fibrillation;myocardial injury;prevention;thoracic surgery
Publication Date: 25-Aug-2023
Publisher: The Lancet
Citation: Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, Reimer C, McLean SR, Srinathan SK, Reyes JCT, Grande AM, Tallada AG, Sessler DI, Fleischmann E, Kabon B, Voltolini L, Cruz P, Maziak DE, Gutiérrez-Soriano L, McIntyre WF, Tandon V, Martínez-Téllez E, Guerra-Londono JJ, DuMerton D, Wong RHL, McGuire AL, Kidane B, Roux DP, Shargall Y, Wells JR, Ofori SN, Vincent J, Xu L, Li Z, Eikelboom JW, Jolly SS, Healey JS, Devereaux PJ; COP-AF Investigators. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023 Aug 25:S0140-6736(23)01689-6. doi: 10.1016/S0140-6736(23)01689-6. Epub ahead of print. PMID: 37640035.
Abstract: Background Higher levels of inflammatory biomarkers are associated with an increased risk of perioperative atrial fibrillation (AF) and myocardial injury after noncardiac surgery (MINS). Colchicine is an anti-inflammatory drug that may prevent these complications. Methods We performed an international, randomised trial at 45 sites in 11 countries. Patients aged ≥55 years and undergoing major noncardiac thoracic surgery were randomised to receive oral colchicine 0·5mg twice daily or matching placebo, starting within four hours before surgery and continuing for ten days. Healthcare providers, patients, data collectors, and adjudicators were blinded to treatment assignment. The co-primary outcomes were clinically important perioperative AF and MINS during 14 days of follow-up. This trial is registered at ClinicalTrials.gov (NCT03310125). Findings We enrolled 3209 patients between February 14, 2018, and June 27, 2023. Clinically important AF developed in 103 of 1608 (6·4%) patients assigned to colchicine, and 120 of 1601 (7·5%) patients assigned to placebo, hazard ratio (HR) 0·85 (95% confidence interval [CI] 0·65-1·10), absolute risk reduction (ARR) 1·1%, 95% CI -0·7-2·8, p=0.22. MINS occurred in 295 (18·3%) patients assigned to colchicine, and 325 (20·3%) patients assigned to placebo, HR 0·89 (95% CI 0·76-1·05), ARR 2·0%, 95% CI -0·8-4·7, p=0.16. Non-infectious diarrhoea was more common in the colchicine group, 134 (8·3%) versus 38 (2·4%) events, HR 3·64 (95% CI 2·54-5·22), but did not prolong median length of hospital stay and led to only one readmission.. Interpretation In patients undergoing major noncardiac thoracic surgery, administration of colchicine did not significantly reduce the incidence of the co-primary outcomes clinically important AF or MINS. While colchicine increased the risk of mostly benign non-infectious diarrhoea, there was an encouraging trend of fewer cardiovascular events with colchicine that requires further research.
Rights: This content is published Open Access under Creative Commons license: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
URI: http://hdl.handle.net/11375/29541
Identifier: https://doi.org/10.1016/S0140-6736(23)01689-6
Appears in Collections:Medicine Publications

Files in This Item:
File Description SizeFormat 
COP-AF Main paper Revision1 final clean no endnote.docx
Access is allowed from: 2024-08-01
49.1 kBMicrosoft Word XMLView/Open
COP-AF_Results Paper_Supplementary Appendix_2023-08-05.docx
Access is allowed from: 2024-08-01
46.34 kBMicrosoft Word XMLView/Open
COP-AF Main paper Figure 1_revised.docx
Access is allowed from: 2024-08-01
40.09 kBMicrosoft Word XMLView/Open
Figure2_A_Clinical_important_AF_02AUG23.pdf
Access is allowed from: 2024-08-01
77.58 kBAdobe PDFView/Open
Figure2_B_MINS_02AUG23.pdf
Access is allowed from: 2024-08-01
77.58 kBAdobe PDFView/Open
Figure3_A_forest_plot_primary_CPAF_01AUG23.pdf
Access is allowed from: 2024-08-01
158.66 kBAdobe PDFView/Open
Figure3_B_forest_plot_primary_MINS_01AUG23.pdf
Access is allowed from: 2024-08-01
158.61 kBAdobe PDFView/Open
Show full item record Statistics


Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.

Sherman Centre for Digital Scholarship     McMaster University Libraries
©2022 McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8 | 905-525-9140 | Contact Us | Terms of Use & Privacy Policy | Feedback

Report Accessibility Issue